According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase ...

Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...

Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...

Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in ...

Treatment with baloxavir marboxil significantly reduced the risk of onward transmission of influenza within households.

The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household ...

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – – This is the first time that any antiviral used in ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir marboxil), an antiviral ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir ...

Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...